Cyclica Forms Multi-Year and Multi-Project Drug Discovery Partnership with the Genome Institute of Singapore
Summary
Cyclica and GIS will carry out research efforts spanning from polypharmacology profiling to novel compound design for diverse drug discovery programs in oncology and related diseases. By empowering researchers and healthcare institutes who are at the forefront of innovation, Cyclica and GIS will pave the way to decentralize the drug discovery process and develop the next generation of improved treatments for patients based on the individual’s disease features. It has the potential to rapidly grow the arsenal of new drugs in our fight against diseases like cancer, especially in an era of genomic medicine where physicians and scientists can better define the underlying genetic and molecular drivers of cancers.” Professor Liu Jianjun, Deputy Executive Director at GIS, added, “Our ability to harness advanced genomic technologies has enhanced our discovery of genetic contributions to a spectrum of diseases, including cancer. This opportunity to make a meaningful contribution and impact to patients are common values we share with our partners at GIS,” said Dr. Verner De Biasi, VP, Global Head of Strategic Partnerships at Cyclica. With a world-class team with deep roots in industry and a first-in-class integrated drug discovery platform, Cyclica will spark a surge of innovation through a combination of venture creation and partnerships with early-stage and emerging biotech companies.